The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia
Mian Muhammad Hassan Ahmed
60 participants
May 1, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone. The hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone. The control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.
Eligibility
Inclusion Criteria3
- month to 12 years
- Both genders
- Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition
Exclusion Criteria8
- Hospitalized within 14 days prior to the study
- Known TB exposure
- Active varicella or herpes simplex infection
- Allergy to the study medication
- Currently taking melatonin
- Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care
- Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption
- Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1 mg/dose in infants and 2.5 to 3mg/dose in children three times a day for 14 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06949904